James A. Hayward Ph.D., Sc.D.
Net Worth

Last updated:

What is James A. Hayward Ph.D., Sc.D. net worth?

The estimated net worth of Dr. James A. Hayward Ph.D., Sc.D. is at least $9,236,097 as of 20 Nov 2014. He owns shares worth $1,403,697 as insider and has received compensation worth at least $7,832,400 in Applied DNA Sciences, Inc..

What is the salary of James A. Hayward Ph.D., Sc.D.?

Dr. James A. Hayward Ph.D., Sc.D. salary is $391,620 per year as Chairman, Pres & Chief Executive Officer in Applied DNA Sciences, Inc..

How old is James A. Hayward Ph.D., Sc.D.?

Dr. James A. Hayward Ph.D., Sc.D. is 71 years old, born in 1954.

What stocks does James A. Hayward Ph.D., Sc.D. currently own?

As insider, Dr. James A. Hayward Ph.D., Sc.D. owns shares in one company:

Company Title Shares Price per share Total value
Applied DNA Sciences, Inc. (APDN) Chairman, Pres & Chief Executive Officer 392,094 $3.58 $1,403,697

What does Applied DNA Sciences, Inc. do?

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

James A. Hayward Ph.D., Sc.D. insider trading

Applied DNA Sciences, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Warrants 76,923 $3.24 $249,231
Purchase
Common Stock 76,923 $3.24 $249,231
Purchase
Common Stock, $.001 par value 234,400 $0.13 $30,472
Purchase
Common Stock, $.001 par value 10,000 $0.19 $1,850
Purchase
Common Stock, $.001 par value 10,000 $0.2 $2,000
Purchase
Common Stock, $.001 par value 5,000 $0.3 $1,515

Applied DNA Sciences key executives

Applied DNA Sciences, Inc. executives and other stock owners filed with the SEC: